Axsome Therapeutics annual revenue
2022
2023
2024
2025
Axsome Therapeutics Revenue Growth & History (AXSM)
Axsome Therapeutics reported $638.5M in revenue for fiscal 2025, an increase of 65.55% from the previous fiscal year.
View full Axsome Therapeutics company overviewAxsome Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $638.5M | $252.8M | +65.55% |
| 2024 | 2024-12-31 | $385.7M | $115.1M | +42.53% |
| 2023 | 2023-12-31 | $270.6M | $220.6M | +440.80% |
| 2022 | 2022-12-31 | $50.0M | — | — |
Axsome Therapeutics quarterly revenue
Q2.21
Q3.21
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $218.4M | $68.3M | +45.54% |
| Q1 2026 | 2026-03-31 | $191.2M | $69.7M | +57.42% |
| Q4 2025 | 2025-12-31 | $196.0M | $77.2M | +65.03% |
| Q3 2025 | 2025-09-30 | $171.0M | $66.2M | +63.22% |
| Q2 2025 | 2025-06-30 | $150.0M | $62.9M | +72.13% |
| Q1 2025 | 2025-03-31 | $121.5M | $46.5M | +61.95% |
| Q4 2024 | 2024-12-31 | $118.8M | $47.2M | +66.04% |
| Q3 2024 | 2024-09-30 | $104.8M | $47.0M | +81.27% |
| Q2 2024 | 2024-06-30 | $87.2M | $40.5M | +86.65% |
| Q1 2024 | 2024-03-31 | $75.0M | −$19.6M | −20.70% |
| Q4 2023 | 2023-12-31 | $71.5M | — | — |
| Q3 2023 | 2023-09-30 | $57.8M | $40.9M | +243.07% |
| Q2 2023 | 2023-06-30 | $46.7M | $37.9M | +429.48% |
| Q1 2023 | 2023-03-31 | $94.6M | — | — |
| Q3 2022 | 2022-09-30 | $16.8M | $16.8M | — |
| Q2 2022 | 2022-06-30 | $8.8M | $8.8M | — |
| Q3 2021 | 2021-09-30 | $0 | — | — |
| Q2 2021 | 2021-06-30 | $0 | — | — |
Axsome Therapeutics revenue growth trends
Axsome Therapeutics's latest reported quarter, Q2 2026, generated $218.4M in revenue, an increase of 45.54% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Axsome Therapeutics source filings ↗